Sekar Kathiresan is CEO at Verve Therapeutics, Inc. (VERV). They have made 8 open-market trades across 1 company since 2021, most recently 2025-07-25.
CIK 0001864112
1 open-market purchase totalling $48K since 2021, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VERV | 346,686 | $3.9M |
Shares reported on the most recent Form 4, priced at the 2025-04-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERV | SELL | 2025-04-02 | 2025-04-03 | $4.15 | $41K | +34.3% | +39.5% | +203.0% |
| VERV | SELL | 2022-10-03 | 2022-10-05 | $33.65 | $3.4M | -9.3% | -12.3% | -47.0% |
| VERV | SELL | 2022-08-10 | 2022-08-11 | $29.90 | $1.5M | +8.3% | +13.5% | -41.9% |
| VERV | SELL | 2022-07-19 | 2022-07-21 | $29.90 | $1.5M | -27.1% | +0.9% | -4.7% |
| VERV | SELL | 2022-01-04 | 2022-01-06 | $39.90 | $75K | +7.9% | -10.5% | -34.7% |
| VERV | SELL | 2021-12-27 | 2021-12-29 | $40.14 | $3.9M | -10.2% | -21.0% | -30.0% |
| VERV | SELL | 2021-12-22 | 2021-12-27 | $39.11 | $6.7M | -19.2% | -24.4% | -40.8% |
| VERV | BUY | 2021-06-21 | 2021-06-21 | $19.00 | $48K | +43.6% | +46.5% | +39.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.